Kyverna Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
KYTX$4.88+5.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share data)
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $224,287 | $34,647 |
| Available-for-sale marketable securities | 145,507 | 22,896 |
| Prepaid expenses and other current assets | 5,694 | 3,121 |
| Total current assets | 375,488 | 60,664 |
| Restricted cash | 570 | 565 |
| Property and equipment, net | 2,714 | 2,326 |
| Operating lease right-of-use assets | 8,486 | 6,494 |
| Finance lease right-of-use assets | 1,552 | 1,790 |
| Other non-current assets | 1,174 | 3,356 |
| Total assets | $389,984 | $75,195 |
| Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | ||
| Current liabilities | ||
| Accounts payable | $7,451 | $4,358 |
| Accrued compensation | 1,363 | 2,812 |
| Accrued license expense – related party | 6,250 | 6,250 |
| Other accrued expenses and current liabilities | 3,083 | 3,519 |
| Operating lease liabilities, short-term portion | 2,739 | 1,964 |
| Finance lease liabilities, short-term portion | 979 | 956 |
| Total current liabilities | 21,865 | 19,859 |
| Operating lease liabilities, net of short-term portion | 6,461 | 5,238 |
| Finance lease liabilities, net of short-term portion | 667 | 921 |
| Total liabilities | 28,993 | 26,018 |
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible preferred stock, no par value; no shares authorized, issued and outstanding as of March 31, 2024; $0.00001 par value, 114,556,997 shares authorized as of December 31, 2023; 114,556,997 shares issued and outstanding as of December 31, 2023; liquidation preference of $181,250 as of December 31, 2023 | — | 180,574 |
| Stockholders’ equity (deficit) | ||
| Preferred stock, 10,000,000 shares authorized, $0.00001 par value, no shares issued and outstanding as of March 31, 2024; no shares authorized, issued, and outstanding as of December 31, 2023 | — | — |
| Common stock, $0.00001 par value; 490,000,000 and 140,492,016 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 43,115,244 and 1,250,103 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | — | — |
| Additional paid-in capital | 523,728 | 4,642 |
| Accumulated other comprehensive income (loss) | (1) | 4 |
| Accumulated deficit | (162,736) | (136,043) |
| Total stockholders’ equity (deficit) | 360,991 | (131,397) |
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $389,984 | $75,195 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.